Table 1.
Demographic, clinical and tracer dose characteristics of schizophrenia patients and healthy controls groups
| Patients (n = 12) |
Healthy controls (n = 13) |
Test statistic | ||||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | F (df) | p | |
| Age at scan (mean years, SD) | 38.5 | 9.68 | 34.2 | 9.08 | 0.112 (23) | 0.25 |
| Gender (male/female) | 12/00 | 13/00 | ||||
| Handedness: right-handed (%) | 100% | 100% | ||||
| PANSS total score, baseline (mean, SD) | 61.5 | 9.70 | n/a | n/a | n/a | n/a |
| Duration of illness in months (mean, SD) | 149.5 | 78.3 | n/a | n/a | n/a | n/a |
| Total antipsychotic dose at baseline (mean CPZ equivalents, SD) | 360.3 | 274.0 | n/a | n/a | n/a | n/a |
| Antipsychotics used (% of second generation) | 92% | n/a | n/a | n/a | n/a | |
| Injected activity (MBq) | 419.3 | 42.7 | 381.2 | 76.2 | 0.843 (23) | 0.14 |
| Injected mass (μg/Kg) | 3.35 | 1.35 | 3.12 | 1.06 | 0.354 (23) | 0.63 |